Chronic kidney disease (CKD) is a growing public health issue. The Centers for Disease Control and Prevention estimates that one in seven Americans, about 35.5 million people, have CKD. A serious form of the disease is antibody-mediated glomerulonephritis (AGN), where antibodies attack the kidney’s glomeruli and cause inflammation and tissue injury.
Researchers reported new results in the Journal of Clinical Investigation Insight using a murine model of AGN. The work was led by Partha Biswas of the Renaissance School of Medicine at Stony Brook University. The team observed immune cells inside the kidney and focused on metabolically reprogrammed neutrophils.
They found that neutrophils in the nephritic kidney increase expression and function of the glucose transporter Glut1. The researchers showed that Glut1 activity in inflammatory cells is necessary for AGN to progress. Disabling Glut1 in neutrophils reduced tissue-damaging effector molecules in both early and late stages, while renal cytokine and chemokine production fell only in the late stage.
Treatment with a Glut1 inhibitor improved kidney pathology in AGN mice. The authors say targeting neutrophil metabolism may be a promising therapeutic strategy for AGN and possibly other forms of CKD. The research was supported in part by the National Institutes of Health.
Difficult words
- glomerulonephritis — inflammation of the kidney's tiny filtering units
- neutrophil — a white blood cell that fights infectionsneutrophils
- reprogram — to change how a cell works or behavesreprogrammed
- glucose transporter — a protein that moves sugar into cells
- inhibitor — a substance that stops or reduces activity
- cytokine — a small protein cells use to send signals
- pathology — damage or disease seen in an organ
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- The authors suggest targeting neutrophil metabolism as a therapy. What do you think are possible benefits or risks of this approach?
- The article says one in seven Americans have CKD. How might this fact affect public health priorities in your community?
- If a treatment improves kidney pathology in mice, what steps do you think are needed before it could be used in people?
Related articles
Climate shocks, crop losses and health risks in Africa
Climate shocks in parts of Africa are hurting crops and helping pests and mosquitoes spread. Farmers face failed harvests and public health risks like malaria and cholera, while experts call for better infrastructure and funding.
Antibody and EGFR–STAT1 pathway point to new fibrosis treatments
Researchers at Yale found a human antibody that blocks epiregulin and lowers fibrosis markers. They also show EGFR activates STAT1 in fibroblasts, suggesting two treatment paths: block epiregulin or target the EGFR–STAT1 pathway.
New inflammatory pathway may explain some rheumatoid arthritis treatment failures
A Washington State University study found that a lesser-known TWEAK–Fn14 pathway can join with TNF to increase inflammation. Blocking Fn14 reduced this surge and may explain why some patients do not respond to TNF inhibitors.
Mindfulness helps couples under financial stress
A University of Georgia study of over 400 couples with children found that higher mindfulness links to greater confidence the relationship will survive stress. Mindfulness also related to better relationship quality and stronger co-parenting.